Table 4 Estimates of effects and quality ratings for comparison of drugs to prevent cardiorenal outcomes
Comparison | Direct evidence | Indirect evidence | Network meta-analysis | |||
|---|---|---|---|---|---|---|
RR [95% CI] | Quality of evidence | RR [95% CI] | Quality of evidence | RR [95% CI] | Quality of evidence | |
MACE | ||||||
SGLT2i vs Placebo | 0.83 (0.77,0.90) | High | Not estimablea | – | 0.84 (0.78,0.90) | High |
GLP-1 RA vs Placebo | 0.86 (0.78,0.94) | High | Not estimablea | – | 0.86 (0.78,0.94) | High |
Finerenone vs Placebo | 0.89 (0.75,1.05) | High | Not estimablea | – | 0.88 (0.80,0.97) | High |
GLP-1 RA vs SGLT2i | – | – | 1.03 (0.91,1.16) | Moderateb | 1.03 (0.91,1.16) | Moderateb |
Finerenone vs SGLT2i | – | – | 1.06 (0.88,1.28) | Moderateb | 1.05 (0.93,1.19) | Moderateb |
Finerenone vs GLP-1 RA | – | – | 1.03 (0.90,1.17) | High | 1.03 (0.90,1.17) | High |
Renal outcome | ||||||
SGLT2i vs Placebo | 0.67 (0.60,0.74) | High | Not estimablea | – | 0.67 (0.60,0.74) | High |
GLP-1 RA vs Placebo | 0.90 (0.80,1.02) | High | Not estimablea | – | 0.90 (0.80,1.02) | High |
Finerenone vs Placebo | 0.86 (0.79,0.93) | High | Not estimablea | – | 0.86 (0.79,0.93) | High |
GLP-1 RA vs SGLT2i | – | – | 1.36 (1.16,1.59) | Moderateb | 1.36 (1.16,1.59) | Moderateb |
Finerenone vs SGLT2i | – | – | 1.29 (1.13,1.47) | Moderateb | 1.29 (1.13,1.47) | Moderateb |
Finerenone vs GLP-1 RA | – | – | 0.95 (0.82,1.10) | High | 0.95 (0.82,1.10) | High |
HHF | ||||||
SGLT2i vs Placebo | 0.60 (0.53,0.68) | High | Not estimablea | – | 0.60 (0.53,0.68) | High |
GLP-1 RA vs Placebo | 0.90 (0.74,1.09) | High | Not estimablea | – | 0.90 (0.73,1.09) | High |
Finerenone vs Placebo | 0.79 (0.67,0.92) | High | Not estimablea | – | 0.79 (0.67,0.92) | High |
GLP-1 RA vs SGLT2i | – | – | 1.49 (1.18,1.89) | Moderateb | 1.49 (1.18,1.89) | Moderateb |
Finerenone vs SGLT2i | – | – | 1.31 (1.07,1.61) | Moderateb | 1.31 (1.07,1.61) | Moderateb |
Finerenone vs GLP-1 RA | – | – | 0.88 (0.68,1.14) | High | 0.88 (0.68,1.14) | High |
CVD | ||||||
SGLT2i vs Placebo | 0.86 (0.77,0.96) | High | Not estimablea | – | 0.86 (0.77,0.96) | High |
GLP-1 RA vs Placebo | 0.90 (0.75,1.08) | High | Not estimablea | – | 0.90 (0.75,1.08) | High |
Finerenone vs Placebo | 0.88 (0.76,1.02) | High | Not estimablea | – | 0.88 (0.76,1.02) | High |
GLP-1 RA vs SGLT2i | – | – | 1.04 (0.85,1.29) | Moderateb | 1.04 (0.85,1.29) | Moderateb |
Finerenone vs SGLT2i | – | – | 1.02 (0.85,1.23) | Moderateb | 1.02 (0.85,1.23) | Moderateb |
Finerenone vs GLP-1 RA | – | – | 0.98 (0.78,1.23) | High | 0.98 (0.78,1.23) | High |
ACD | ||||||
SGLT2i vs Placebo | 0.90 (0.81,0.99) | High | Not estimablea | – | 0.89 (0.81,0.99) | High |
GLP-1 RA vs Placebo | 0.89 (0.78,1.02) | High | Not estimablea | – | 0.89 (0.77,1.02) | High |
Finerenone vs Placebo | 0.90 (0.80,1.00) | High | Not estimablea | – | 0.90 (0.80,1.00) | High |
GLP-1 RA vs SGLT2i | – | – | 0.99 (0.84,1.18) | Moderateb | 0.99 (0.84,1.18) | Moderateb |
Finerenone vs SGLT2i | – | – | 1.00 (0.86,1.16) | Moderateb | 1.00 (0.86,1.16) | Moderateb |
Finerenone vs GLP-1 RA | – | – | 1.01 (0.85,1.20) | High | 1.01 (0.85,1.20) | High |